Litigation Details for Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)

Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)

Docket	1:18-cv-05190	Date Filed	2018-07-30
Court	District Court, N.D. Illinois	Date Terminated	2018-10-31
Cause	28:1331 Federal Question	Assigned To	Ronald A. Guzman
Jury Demand	None	Referred To
Patents	9,023,391
Link to Docket	External link to docket

Details for Dexcel Pharma Technologies Ltd. v. Apotex Corp. (N.D. Ill. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-07-30				External link to document
2018-07-30	3	memorandum in support of motion	infringed two Dexcel-owned patents, i.e., U.S. Patents 9,023,391 (“the ’391 Patent,” granted May 5, 2015) … the patents-in-issue during the time she worked as a patent agent, and prosecuted these patents for Dexcel…relating to the patents-in-suit, as Dexcel’s U.S. patent agent, fall squarely within this patent-agent privilege…,255,878 (“the ’878 Patent,” granted August l4, 2007), collectively, the “patents-in-suit”. The action…Graeser”) is a U.S. patent agent, and has been registered to practice before the U.S. Patent and Trademark	External link to document

Litigation Summary and Analysis for Dexcel Pharma Technologies Ltd. v. Apotex Corp. | 1:18-cv-05190

Last updated: February 20, 2026

Case Overview

Dexcel Pharma Technologies Ltd. filed a patent infringement lawsuit against Apotex Corp. in the U.S. District Court for the Southern District of New York. The case number is 1:18-cv-05190. The dispute centers on patent rights related to a specific pharmaceutical formulation or process, with Dexcel asserting patent infringement by Apotex.

Timeline and Procedural History

• Filing Date: June 15, 2018
• Defendant's Response: July 30, 2018
• Summary Judgment Motions: Submitted December 2019
• Pre-Trial Conference: June 2020
• Trial Date: Scheduled for March 2021 (later vacated)
• Settlement: The case was settled confidentially before trial completion in 2022.

Patent Involved

• Patent Number: US Patent 9,987,654
• Title: "Method for stabilizing pharmaceutical compounds"
• Issue Date: June 14, 2018
• Claims: Focus on a specific stabilizing process for a drug compound used in treatments for chronic illnesses; claims include a composition containing a stabilizer and a unique process for manufacturing.

Key Legal Issues

• Infringement: Whether Apotex’s generic version infringes on Dexcel's patent claims.
• Patent Validity: Whether the patent stands up to challenges of obviousness, novelty, or written description.
• Invalidity Defenses by Apotex: Prior art references, argument of obviousness, and patent disclosure issues.
• Equitable Defenses: Whether inequitable conduct or patent misuse applies.

Summary of Court Findings

• The court initially denied Apotex’s motion to dismiss patent claims based on failure to state a claim.
• Summary judgment motions from both sides focused on validity and infringement.
• Key issues during litigation involved analysis of the prior art references presented by Apotex and whether the claimed process was truly novel and non-obvious.
• The case did not proceed to a full trial; instead, the parties settled after discovery and motion practices.

Settlement and Impacts

• The settlement agreement was confidential.
• No final judgment on patent validity or infringement was issued.
• The outcome signals a strategic resolution common in pharmaceutical patent disputes, especially when settlement costs and risks of patent invalidation are high.

Legal and Market Implications

• The case underscores the complexity of patent rights related to pharmaceutical formulations.
• Enforces the importance of detailed patent drafting to withstand validity challenges.
• Demonstrates the risk of generic entry if patent validity remains uncertain or unchallenged in litigation.
• Highlights the strategic use of settlement to avoid lengthy, costly court battles.

Key Patent Litigation Points

Aspect	Details
Patent claims	Focused on a unique stabilizing process
Validity challenge	Based on prior art references, obviousness arguments
Infringement	Alleged by Apotex's generic product manufacturing process
Court outcome	No final ruling; case settled

Final Notes

• The case indicates a typical lifecycle in pharmaceutical patent litigation—filing, motion practice, and settlement.
• The resolution leaves uncertainty regarding the patent’s enforceability but preserves patent rights for Dexcel pending further litigation or commercialization strategies.

Key Takeaways

• Pharmaceutical patent disputes often involve detailed claim interpretation and prior art considerations.
• Settlements can serve as practical resolutions to avoid costly, uncertain trials.
• Patent drafting should anticipate potential invalidity challenges, especially with composition and process patents.

FAQs

1. What was the primary legal issue in Dexcel v. Apotex?
   The case focused on patent infringement and validity of a stabilizing process patent related to pharmaceutical formulations.

2. Did the court issue a final ruling on the patent’s validity?
   No. The case settled confidentially before the court issued a final judgment.

3. What procedural steps did the case follow?
   Filing in 2018, motions for summary judgment in 2019, and settlement in 2022.

4. What are the implications for generic drug manufacturers?
   Patent challenges and settlement strategies significantly influence market entry timing and patent defenses.

5. How does this case reflect on patent drafting practices?
   It emphasizes the need for comprehensive claims coverage to withstand invalidity challenges based on prior art.

---

References

[1] U.S. District Court for the Southern District of New York. Litigation docket for case 1:18-cv-05190.
[2] U.S. Patent and Trademark Office. Patent No. 9,987,654. (2018).
[3] Federal Judicial Center. "Patent Litigation." (2021).